CRDF
Cardiff OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Cardiff keeps validating the onvansertib signal: the ASCO update and the mid-2026 Phase 3 design disclosure both have the potential to confirm a registrational path after the FDA-aligned End-of-Phase 2 meeting. If the data hold and execution stays disciplined, the stock can still re-rate sharply from a very small base.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical execution risk is still high: the market needs the updated CRDF-004 data and Phase 3 plan to preserve the earlier efficacy signal [#SEC-8K-2026-05-14].
Momentum
91
Value
41
Sentiment
92
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.85 · Bull $4.25 · Bear $0.65
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $8.36
Why
Momentum91 · Δ7d -
Value41 · Δ7d +0.1
Sentiment92 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
92
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 90.6 / Value 41.1 / Sentiment 91.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$101.19M
Beta
1.33
Shares Out
67.36M
P/E (TTM) · Derived
-2.2
P/S (TTM)
381.84
P/FCF (TTM) · Derived
-2.26
Rev YoY
-27.3%
EPS YoY
+33.5%
Gross Margin
-
Op Margin
-10719.6%
Net Debt
-$91.75M
Current Ratio
4.20
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology